Klebsiella pneumoniae OXA-48 (CDC & FDA AR Isolate Bank #0160), Lung Infection Model, CFU Data

ITEM 608593

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This model assesses the antimicrobial efficacy of test articles in a tissue infection model. Microbial counts are measured. Klebsiella pneumoniae is a commensal Gram-negative bacterium that can cause life-threatening infections such as bacteremia, peritonitis, lung, and urinary tract infections. It is an important pathogen in hospital settings. This OXA-48 carbapenemases-producing organism is resistant to meropenem and imipenem. It is susceptible to amikacin, aztreonam, extended-spectrum cephalosporin, ciprofloxacin, levofloxacin, colistin, and tigecycline. The CDC & FDA Antimicrobial Resistance Isolate Bank supplied this strain.

SPECIES

Klebsiella pneumoniae

STRAIN COMMON NAME

(#0160)

ORGANISM

Gram-negative Bacteria

INCUBATION CONDITIONS

Aerobic

NOTABLE ANTIBIOTIC RESISTANCE GENE

OXA-48

ANTIBIOTIC RESISTANCE GENES

fosA,oqxA,oqxB,OXA-48,SHV-11

SOURCE

STRAIN SOURCE

CDC & FDA AR Isolate Bank

STRAIN SOURCE ID

AR Bank #0160

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 5 female specific-pathogen-free ICR (CD-1) neutropenic mice are intranasally inoculated with pathogen suspension. Test articles and vehicle are administered per the specification of the study design after inoculation. Doses may be delivered by IV, IV infusion, SC, PO, IM, or IP administration. At 26 hours after infection, animals are humanely euthanized and tissue is aseptically harvested. The collected tissues are homogenized and pathogen counts are determined by dilution plating.

CRITERIA FOR SIGNIFICANCE

A significant (p < 0.05) decrease in the bacterial counts of the treated animals compared to the vehicle control group or the baseline control group was considered a significant difference.

TURNAROUND TIME

STANDARD

30 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei